RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Dermapharm Holding Stock

Dermapharm Holding ROA 2024

Dermapharm Holding ROA

0.03

Ticker

DMP.DE

ISIN

DE000A2GS5D8

WKN

A2GS5D

In 2024, Dermapharm Holding's return on assets (ROA) was 0.03, a -69.62% increase from the 0.1 ROA in the previous year.

Dermapharm Holding Aktienanalyse

What does Dermapharm Holding do?

Dermapharm Holding SE is a German company specializing in the development, manufacturing, and distribution of pharmaceuticals and skincare products. It was founded in 1991 by Dr. Hans-Georg Feldmeier and is headquartered in Grünwald near Munich. Dermapharm is a publicly traded company and has experienced impressive growth in recent years. It operates in the German market for prescription and over-the-counter drugs and also has a wide portfolio of skincare products for various applications. The business model of Dermapharm focuses on the development of new pharmaceuticals and skincare products to meet the needs of patients and consumers. The company maintains a highly scientific research and development department working on innovative therapies and care products. Dermapharm operates in various segments, including dermatological and ophthalmological therapeutics, women and children's health, urology, self-medication, and skincare. The company also offers a wide range of generic products. Some of Dermapharm's well-known products include Acnatac, a combination of Tretinoin and Clindamycin for the treatment of acne, and the gynecological therapy product line Gynofit, which is designed for the treatment of vaginal infections and irritations in women. Furthermore, Dermapharm has developed a comprehensive range of skincare products under its brand Linola. Linola is a brand that focuses on the care of atopic skin, neurodermatitis, and other skin conditions. Linola products are also available in various textures, including lotions, creams, and oils. Over the years, Dermapharm has established a strong presence in the European market and operates in more than 50 countries worldwide. The company also collaborates with external partners and promoters to successfully market its brands and products. Overall, Dermapharm has experienced strong growth thanks to its scientific approach and strong distribution network. The company remains committed to developing new therapies and products to meet the needs of patients and consumers, and to expand its presence on an international level. Dermapharm Holding ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Dermapharm Holding's Return on Assets (ROA)

Dermapharm Holding's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Dermapharm Holding's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Dermapharm Holding's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Dermapharm Holding’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Dermapharm Holding stock

What is the Return on Assets (ROA) of Dermapharm Holding this year?

The Return on Assets (ROA) of Dermapharm Holding is 0.03 undefined this year.

What was the ROA of Dermapharm Holding compared to the previous year?

The ROA of Dermapharm Holding has increased by -69.62% compared to the previous year.

What consequences do high ROA have for investors of Dermapharm Holding?

A high ROA is advantageous for investors of Dermapharm Holding, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Dermapharm Holding?

A low ROA can be unfavorable for investors of Dermapharm Holding as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Dermapharm Holding affect the company?

An increase in ROA of Dermapharm Holding can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Dermapharm Holding impact the company?

A reduction in the ROA of Dermapharm Holding can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Dermapharm Holding?

Some factors that can influence the ROA of Dermapharm Holding include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Dermapharm Holding important for investors?

The ROA of Dermapharm Holding is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Dermapharm Holding take to improve ROA?

To improve ROA, Dermapharm Holding can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Dermapharm Holding pay?

Over the past 12 months, Dermapharm Holding paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Dermapharm Holding is expected to pay a dividend of 1.14 EUR.

What is the dividend yield of Dermapharm Holding?

The current dividend yield of Dermapharm Holding is .

When does Dermapharm Holding pay dividends?

Dermapharm Holding pays a quarterly dividend. This is distributed in the months of July, July, July, July.

How secure is the dividend of Dermapharm Holding?

Dermapharm Holding paid dividends every year for the past 0 years.

What is the dividend of Dermapharm Holding?

For the upcoming 12 months, dividends amounting to 1.14 EUR are expected. This corresponds to a dividend yield of 3.09 %.

In which sector is Dermapharm Holding located?

Dermapharm Holding is assigned to the 'Health' sector.

Wann musste ich die Aktien von Dermapharm Holding kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Dermapharm Holding from 7/2/2024 amounting to 0.88 EUR, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.

When did Dermapharm Holding pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of Dermapharm Holding in the year 2023?

In the year 2023, Dermapharm Holding distributed 2.17 EUR as dividends.

In which currency does Dermapharm Holding pay out the dividend?

The dividends of Dermapharm Holding are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Dermapharm Holding stock can be added to a savings plan with the following providers: Trade Republic and Scalable Capital

Andere Kennzahlen von Dermapharm Holding

Our stock analysis for Dermapharm Holding Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Dermapharm Holding Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.